About 640 results

ALLMedicine™ Superior Vena Cava Syndrome Center

Research & Reviews  240 results

Hematologic and Oncologic Emergencies.
Critical Care Nursing Quarterly; Holden K, Rao S et. al.

Nov 24th, 2022 - This article reviews both hematologic and oncologic emergencies that may be seen in the intensive care setting. Hematologic emergencies, including autoimmune hemolytic anemia, thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, and dis...

Surgical treatment for Behcet's disease with acute superior vena cava syndrome.
Journal of Cardiac Surgery; Zhang Y, Wang Z et. al.

Nov 10th, 2022 - Behcet's disease (BD) is a multisystem vasculitis with unknown etiology. The involvement of superior vena cava (SVC) is reported in less than 2% of patients with BD. We report a patient with acute edema of neck and face associated with dyspnea as ...

An unusual case of superior vena cava syndrome.
Clinical Medicine (London, England); Huda AB, Culasso M

Oct 12th, 2022 - An unusual case of superior vena cava syndrome.|2022|Huda AB,Culasso M,|chemically induced,diagnosis,adverse effects,prevention & control,

Superior vena cava syndrome-induced hemoptysis.
The American Journal of the Medical Sciences; Saadi WA, Al Khalili H et. al.

Sep 25th, 2022 - Superior vena cava (SVC) syndrome resulting from obstruction of the blood flow to the superior vena cava is rarely reported to present with life-threatening hemoptysis. The pathogenesis and the underlying mechanism are still not well described in ...

Mid-Term Patency of Spiral Saphenous Vein Graft for Malignant Superior Vena Cava Syndrome.
Vascular and Endovascular Surgery; Inoue T, Fujii K et. al.

Aug 13th, 2022 - Reports documenting the mid-term patency of spiral saphenous vein grafts for superior vena cava syndrome in patients with advanced thoracic malignancy are, so far, scarce. The present report describes a 69-year-old man who suffered superior vena c...

see more →

Clinicaltrials.gov  1 results

Efficacy and Safety of Cetuximab in Combination With Cisplatin Gemcitabine as First-Line Therapy in Advanced NSCLC

Nov 20th, 2007 - Criteria for inclusion Signed written informed consent Male or female ≥18 years of age Cito-histological diagnosis of NSCLC, stage IV Performance Status = 0 or 1 Measurable disease on CT scan - RECIST criteria White blood count ≥ 3 x 109/L, Neutro...

see more →

News  14 results

Clinical Presentation of Squamous NSCLC

Apr 2nd, 2021 - Transcript:Benjamin Levy, MD: Hello, and thank you for joining us for this OncLive Peer Exchange. Until recently, little progress had been made in the area of squamous non-small cell lung cancer. Now, with the excitement of recent positive trials ...

Novel Molecular Targets for Drug Development in Non-GIST Sarcomas

Dec 20th, 2020 - William D. Tap, MD Abstract The characterization of molecular abnormalities implicated in the tumorigenesis of sarcomas is being increasingly applied to the classification, prognostication and, in particular situations, management of these ...

From a Distance: Managing Side Effects in Outpatients

Dec 5th, 2020 - Oncology nurses know the intricacies of cancer treatment. They know how to interact with patients in distress. And they know how to handle long-distance relationships. It is a skill nurses have developed in the past 10 years, as cancer treatment h...

Untreated Goiters Larger at Surgery in Men, Minorities, and the Old

Mar 14th, 2016 - Significant disparities exist in the presentation and outcomes of patients with goiters in the United States, with minority ethnic groups, men, and older patients more likely to present with untreated goiters that have become so large they extend ...

David Henry's JCSO podcast, November 2014
Dr. David Henry

Nov 30th, 2014 - Among the items featured in Dr David Henry’s monthly podcast for The Journal of Community and Supportive Oncology, are reports on congestive heart failure during induction with anthracycline-based therapy in patients with acute promyelocytic leuke.

see more →

Patient Education  1 results see all →